Chemed（CHE）株式概要
ケメッド社は、主に米国内の医師、ドクター、正看護師、ホームヘルパー、ソーシャルワーカー、聖職者、ボランティアのネットワークを通じて、患者にホスピス・緩和ケアサービスを提供している。 詳細
CHE Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Chemed Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$488.59 |
| 52週高値 | US$493.47 |
| 52週安値 | US$365.21 |
| ベータ | 0.52 |
| 1ヶ月の変化 | 16.52% |
| 3ヶ月変化 | 26.05% |
| 1年変化 | 6.24% |
| 3年間の変化 | -9.26% |
| 5年間の変化 | 3.51% |
| IPOからの変化 | 4,219.03% |
最新ニュース
ナラティブの更新 • Jun 29
CHE: Strong Q1 Results And Buybacks Support Balanced Future Return Potential
Analysts have revised their price target on Chemed to $500 from $580, reflecting updated assumptions for slightly higher discount rates, revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for Chemed Chemed reported Q1 revenue of $657.5 million, which was 1.6% higher year over year and 1.2% above analyst expectations, according to recent earnings coverage.
ナラティブの更新 • Jun 15
CHE: Share Repurchases And Stable Margins Will Support Balanced Future Returns
Analysts have kept their Chemed price target essentially unchanged at about $446.50, with only minimal tweaks to underlying assumptions such as revenue growth, profit margin, and future P/E to reflect updated modeling rather than a shift in overall outlook. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.Recent updates
ナラティブの更新 • Jun 29
CHE: Strong Q1 Results And Buybacks Support Balanced Future Return Potential
Analysts have revised their price target on Chemed to $500 from $580, reflecting updated assumptions for slightly higher discount rates, revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for Chemed Chemed reported Q1 revenue of $657.5 million, which was 1.6% higher year over year and 1.2% above analyst expectations, according to recent earnings coverage.ナラティブの更新 • Jun 15
CHE: Share Repurchases And Stable Margins Will Support Balanced Future Returns
Analysts have kept their Chemed price target essentially unchanged at about $446.50, with only minimal tweaks to underlying assumptions such as revenue growth, profit margin, and future P/E to reflect updated modeling rather than a shift in overall outlook. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.ナラティブの更新 • Jun 01
CHE: Ongoing Buybacks And Stable Margins Will Support Balanced Future Returns
Analysts have nudged their price target on Chemed higher to $446.50 from $443, reflecting updated assumptions around slightly stronger revenue growth, a modestly higher discount rate, stable profit margins, and a lower future P/E multiple. What's in the News Chemed reported that from January 1, 2026 to March 31, 2026, it repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.ナラティブの更新 • Apr 27
CHE: Ongoing Buybacks And Earnings Guidance Will Support Balanced Future Returns
Analysts now see Chemed’s fair value holding at $443, with updated assumptions for revenue growth of 6.52%, a profit margin of 12.54%, and a future P/E of 15.49x shaping their refreshed price target rationale. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares for $197.7 million, representing 3.65% of its shares under the long running buyback program announced in February 2011 (Key Developments).ナラティブの更新 • Apr 10
CHE: Expanded Buybacks And Earnings Guidance Will Support Stronger Future Returns
Analysts have kept their price target for Chemed steady at $443. This reflects updated assumptions around slightly different revenue growth, profit margin and future P/E inputs that do not materially change their overall valuation view.ナラティブの更新 • Mar 27
CHE: Expanded Buybacks And Higher Margins Will Support Stronger Future Returns
Analysts have maintained Chemed's price target at $443, citing updated assumptions for profit margin and forward P/E as key factors behind the reaffirmed view. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, with projected earnings per diluted share in a range of $23.25 to $24.25, excluding certain non cash items such as stock option expenses, tax benefits from stock option exercises, litigation costs and other discrete items (corporate guidance).ナラティブの更新 • Mar 10
CHE: Revised Outlook And Ongoing Buybacks Will Shape Balanced Future Returns
Analysts have revised their price target on Chemed to $443.00 from $555.50, reflecting updated views on revenue growth, profit margins, and the P/E multiple they consider appropriate for the stock. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, projecting earnings per diluted share, excluding specified non cash and discrete items, in a range of $23.25 to $24.25 (company guidance).新しいナラティブ • Feb 27
Repositioned Hospice Mix And Aging Demographics Will Support Stronger Long Term Performance
Catalysts About Chemed Chemed operates VITAS Healthcare, a large hospice provider, and Roto-Rooter, a national plumbing and water restoration service business. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Feb 24
CHE: Stable Margins And Expanded Buybacks Will Support Future Upside
Analysts maintained Chemed's price target at $555.50, citing unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News On February 13, 2026, Chemed increased its equity buyback authorization by US$300 million to a total of US$3.05 billion under its existing repurchase program (Key Developments).ナラティブの更新 • Feb 10
CHE: Stable Margins And Consistent Assumptions Will Support Future Upside
Analysts have maintained their fair value estimate for Chemed at US$555.50 per share, with only small adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a marginally updated price target narrative. Valuation Changes Fair Value: Kept unchanged at US$555.50 per share, indicating no revision to the central valuation output.ナラティブの更新 • Jan 23
CHE: Share Buybacks And Margin Outlook Will Support Future Upside
Analysts now see Chemed's fair value at US$555.50, down from US$582.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions.分析記事 • Jan 16
Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...分析記事 • Oct 31
Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results
It's been a good week for Chemed Corporation ( NYSE:CHE ) shareholders, because the company has just released its...分析記事 • Oct 24
Chemed Corporation (NYSE:CHE) Shares Could Be 38% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Chemed fair value estimate is US$707 Chemed is estimated to be...Seeking Alpha • Oct 06
Chemed Corp: Genius Of The Model Lies In Its Corporate Strategy
Summary Chemed Corp's unconventional structure is masterfully managed with a disciplined focus on operational excellence and shareholder-friendly capital allocation. The company's primary competitive advantage is its brand, a powerful intangible asset cultivated over nearly a century of reliable service and effective marketing. Chemed has constructed a uniquely durable enterprise built to create shareholder value for the long term. Read the full article on Seeking Alphaナラティブの更新 • Sep 03
New Florida CON Sites Will Advance Home-Based And Hospice Care
Chemed’s modest price target increase to $582.25 reflects stable sentiment, as core metrics like future P/E and revenue growth remain virtually unchanged. What's in the News Increased equity buyback authorization by $300 million, bringing total to $2.75 billion.株主還元
| CHE | US Healthcare | US 市場 | |
|---|---|---|---|
| 7D | -0.2% | -0.4% | 0.8% |
| 1Y | 6.2% | 31.5% | 20.6% |
業界別リターン: CHE過去 1 年間で31.5 % の収益を上げたUS Healthcare業界を下回りました。
リターン対市場: CHEは、過去 1 年間で20.6 % のリターンを上げたUS市場を下回りました。
価格変動
| CHE volatility | |
|---|---|
| CHE Average Weekly Movement | 4.2% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: CHE 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: CHEの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1970 | 15,811 | Kevin McNamara | www.chemed.com |
ケメッド社は、主に米国において、医師、ドクター、正看護師、ホームヘルパー、ソーシャルワーカー、聖職者、ボランティアのネットワークを通じて、患者にホスピス・緩和ケアサービスを提供している。同社は2つのセグメントを通じて事業を展開している：VITAS部門とRoto-Rooter部門である。同社は、直営支店、独立請負業者、フランチャイズ加盟店を通じて、家庭用および商業用の顧客に配管工事、排水管清掃、掘削工事、水の修復、その他の関連サービスを提供している。また、患者に直接医療サービスを提供するほか、患者とその家族に精神的・感情的カウンセリングも行っている。ケメッド・コーポレーションは1970年に法人化され、オハイオ州シンシナティに本社を置く。
Chemed Corporation 基礎のまとめ
| CHE 基礎統計学 | |
|---|---|
| 時価総額 | US$6.46b |
| 収益（TTM） | US$259.78m |
| 売上高(TTM) | US$2.54b |
24.9x
PER（株価収益率2.5x
P/SレシオCHE は割高か？
公正価値と評価分析を参照収益と収入
| CHE 損益計算書（TTM） | |
|---|---|
| 収益 | US$2.54b |
| 売上原価 | US$1.72b |
| 売上総利益 | US$822.54m |
| その他の費用 | US$562.75m |
| 収益 | US$259.78m |
直近の収益報告
Mar 31, 2026
次回決算日
Jul 28, 2026
| 一株当たり利益（EPS） | 19.65 |
| グロス・マージン | 32.38% |
| 純利益率 | 10.23% |
| 有利子負債／自己資本比率 | 10.8% |
CHE の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
0.5%
現在の配当利回り13%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/12 16:40 |
| 終値 | 2026/07/10 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Chemed Corporation 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10
| アナリスト | 機関 |
|---|---|
| Adam Feinstein | Barclays |
| Joanna Sylvia Gajuk | BofA Global Research |
| Peter Martin | Citizens JMP Securities, LLC |